Thomas Campbell
Concepts (644)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 27 | 2026 | 83 | 6.970 |
Why?
| | HIV Infections | 116 | 2026 | 3154 | 6.400 |
Why?
| | HIV-1 | 61 | 2023 | 896 | 4.280 |
Why?
| | Anti-HIV Agents | 47 | 2024 | 888 | 3.580 |
Why?
| | Herpesvirus 8, Human | 22 | 2024 | 68 | 3.200 |
Why?
| | Antiretroviral Therapy, Highly Active | 30 | 2023 | 278 | 2.430 |
Why?
| | AIDS-Related Opportunistic Infections | 14 | 2026 | 130 | 1.950 |
Why?
| | Anti-Retroviral Agents | 21 | 2024 | 250 | 1.690 |
Why?
| | Zimbabwe | 21 | 2026 | 76 | 1.620 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2023 | 235 | 1.330 |
Why?
| | Viral Load | 34 | 2023 | 526 | 1.310 |
Why?
| | HIV Seropositivity | 7 | 2021 | 119 | 1.280 |
Why?
| | Biomarkers, Tumor | 3 | 2026 | 1322 | 1.230 |
Why?
| | International Cooperation | 4 | 2018 | 198 | 1.120 |
Why?
| | CD4 Lymphocyte Count | 26 | 2023 | 277 | 1.000 |
Why?
| | Inflammation | 17 | 2026 | 2880 | 0.990 |
Why?
| | Aging | 9 | 2024 | 1966 | 0.940 |
Why?
| | Education, Medical | 3 | 2018 | 276 | 0.930 |
Why?
| | alpha 1-Antichymotrypsin | 1 | 2025 | 4 | 0.890 |
Why?
| | Adult | 103 | 2026 | 40506 | 0.870 |
Why?
| | Gastrointestinal Microbiome | 8 | 2026 | 771 | 0.850 |
Why?
| | Middle Aged | 79 | 2026 | 35928 | 0.850 |
Why?
| | RNA, Viral | 19 | 2014 | 688 | 0.820 |
Why?
| | Humans | 169 | 2026 | 144957 | 0.790 |
Why?
| | Male | 120 | 2026 | 72406 | 0.790 |
Why?
| | Physical Fitness | 2 | 2015 | 209 | 0.790 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2642 | 0.780 |
Why?
| | DNA, Viral | 12 | 2013 | 358 | 0.750 |
Why?
| | Female | 113 | 2026 | 78376 | 0.730 |
Why?
| | Tuberculosis | 7 | 2023 | 291 | 0.720 |
Why?
| | Drug Resistance, Viral | 8 | 2015 | 123 | 0.700 |
Why?
| | Herpesviridae Infections | 7 | 2021 | 150 | 0.690 |
Why?
| | Viremia | 6 | 2011 | 158 | 0.690 |
Why?
| | Antibodies, Viral | 8 | 2023 | 672 | 0.670 |
Why?
| | AIDS Dementia Complex | 7 | 2015 | 52 | 0.650 |
Why?
| | Antibiotics, Antineoplastic | 4 | 2026 | 139 | 0.640 |
Why?
| | Coinfection | 6 | 2019 | 141 | 0.640 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2023 | 1129 | 0.630 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2004 | 89 | 0.610 |
Why?
| | Reverse Transcriptase Inhibitors | 6 | 2015 | 87 | 0.600 |
Why?
| | Nursing Staff, Hospital | 1 | 2022 | 158 | 0.600 |
Why?
| | Lamivudine | 6 | 2017 | 65 | 0.590 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2004 | 27 | 0.580 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 87 | 0.580 |
Why?
| | Homosexuality, Male | 6 | 2026 | 222 | 0.570 |
Why?
| | Anemia | 3 | 2023 | 188 | 0.560 |
Why?
| | Vitamin D Deficiency | 3 | 2017 | 186 | 0.560 |
Why?
| | Breast Neoplasms | 3 | 2026 | 2456 | 0.550 |
Why?
| | HIV | 8 | 2023 | 250 | 0.540 |
Why?
| | Vitamin D | 5 | 2018 | 400 | 0.530 |
Why?
| | Mass Screening | 1 | 2026 | 1348 | 0.510 |
Why?
| | Plasma | 4 | 2015 | 225 | 0.500 |
Why?
| | Prospective Studies | 23 | 2026 | 7997 | 0.500 |
Why?
| | Micronutrients | 4 | 2018 | 96 | 0.490 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 24 | 0.490 |
Why?
| | Health Resources | 5 | 2019 | 130 | 0.480 |
Why?
| | Biomarkers | 14 | 2026 | 4275 | 0.480 |
Why?
| | Internationality | 5 | 2019 | 156 | 0.470 |
Why?
| | Motor Activity | 3 | 2015 | 722 | 0.460 |
Why?
| | RNA, Catalytic | 4 | 1997 | 189 | 0.450 |
Why?
| | Burnout, Professional | 1 | 2022 | 484 | 0.440 |
Why?
| | Benzoxazines | 6 | 2017 | 31 | 0.430 |
Why?
| | Developing Countries | 10 | 2020 | 318 | 0.430 |
Why?
| | Awareness | 1 | 2015 | 110 | 0.430 |
Why?
| | Cardiotoxicity | 2 | 2026 | 33 | 0.430 |
Why?
| | Zidovudine | 7 | 2017 | 77 | 0.420 |
Why?
| | Quality of Life | 6 | 2019 | 3192 | 0.410 |
Why?
| | HIV Integrase Inhibitors | 1 | 2015 | 78 | 0.410 |
Why?
| | C-Reactive Protein | 5 | 2015 | 417 | 0.400 |
Why?
| | Bronchoalveolar Lavage Fluid | 6 | 2021 | 636 | 0.400 |
Why?
| | Monocytes | 2 | 2023 | 538 | 0.400 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 206 | 0.390 |
Why?
| | South America | 8 | 2026 | 57 | 0.380 |
Why?
| | Prevotella | 2 | 2025 | 26 | 0.370 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 4 | 2020 | 20 | 0.370 |
Why?
| | Doxorubicin | 2 | 2026 | 397 | 0.360 |
Why?
| | Disease Progression | 11 | 2025 | 2852 | 0.360 |
Why?
| | Treatment Outcome | 22 | 2023 | 11695 | 0.360 |
Why?
| | Aged | 24 | 2025 | 25947 | 0.360 |
Why?
| | Sarcopenia | 1 | 2013 | 91 | 0.350 |
Why?
| | Receptors, CCR5 | 5 | 2021 | 60 | 0.350 |
Why?
| | Malnutrition | 3 | 2018 | 86 | 0.350 |
Why?
| | Case-Control Studies | 9 | 2025 | 3608 | 0.340 |
Why?
| | Pharmacogenetics | 4 | 2026 | 173 | 0.320 |
Why?
| | Prevalence | 10 | 2026 | 2836 | 0.320 |
Why?
| | Faculty, Medical | 4 | 2018 | 303 | 0.320 |
Why?
| | Osteoporosis | 1 | 2013 | 236 | 0.320 |
Why?
| | Africa | 6 | 2020 | 116 | 0.310 |
Why?
| | Antineoplastic Agents, Phytogenic | 3 | 2020 | 177 | 0.310 |
Why?
| | Neutropenia | 1 | 2010 | 155 | 0.310 |
Why?
| | Accidental Falls | 1 | 2012 | 222 | 0.300 |
Why?
| | Antiviral Agents | 5 | 2017 | 768 | 0.300 |
Why?
| | Drug Therapy, Combination | 10 | 2020 | 1048 | 0.300 |
Why?
| | Virus Replication | 6 | 2006 | 529 | 0.300 |
Why?
| | Sexual Behavior | 4 | 2020 | 492 | 0.300 |
Why?
| | Cross-Sectional Studies | 10 | 2022 | 5872 | 0.290 |
Why?
| | Tenofovir | 6 | 2017 | 295 | 0.290 |
Why?
| | Longitudinal Studies | 10 | 2026 | 2947 | 0.290 |
Why?
| | Thrombocytopenia | 1 | 2010 | 205 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2025 | 1721 | 0.280 |
Why?
| | Emergency Medical Services | 1 | 2015 | 696 | 0.280 |
Why?
| | Advance Care Planning | 1 | 2012 | 243 | 0.280 |
Why?
| | Viral Proteins | 2 | 2008 | 355 | 0.270 |
Why?
| | Genetic Variation | 4 | 2008 | 984 | 0.270 |
Why?
| | Etoposide | 4 | 2023 | 167 | 0.260 |
Why?
| | Professional Competence | 2 | 2018 | 98 | 0.260 |
Why?
| | Microbiota | 4 | 2018 | 781 | 0.260 |
Why?
| | Sex Characteristics | 3 | 2023 | 791 | 0.260 |
Why?
| | Atazanavir Sulfate | 3 | 2016 | 42 | 0.260 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1099 | 0.250 |
Why?
| | Cohort Studies | 20 | 2019 | 5965 | 0.250 |
Why?
| | Cyclopropanes | 6 | 2017 | 83 | 0.250 |
Why?
| | Incidence | 9 | 2026 | 2883 | 0.250 |
Why?
| | Sexual and Gender Minorities | 3 | 2021 | 251 | 0.250 |
Why?
| | Alkynes | 6 | 2017 | 66 | 0.250 |
Why?
| | Schools, Medical | 2 | 2018 | 157 | 0.250 |
Why?
| | Survival Analysis | 4 | 2015 | 1385 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1416 | 0.250 |
Why?
| | Drug Monitoring | 1 | 2010 | 395 | 0.250 |
Why?
| | Risk Factors | 18 | 2025 | 10792 | 0.250 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 368 | 0.250 |
Why?
| | Asia | 5 | 2016 | 70 | 0.240 |
Why?
| | Feces | 5 | 2025 | 513 | 0.230 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 917 | 0.230 |
Why?
| | Treatment Failure | 8 | 2018 | 365 | 0.230 |
Why?
| | Sex Factors | 4 | 2016 | 2114 | 0.230 |
Why?
| | Genotype | 7 | 2023 | 1835 | 0.230 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2005 | 10 | 0.230 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2018 | 428 | 0.220 |
Why?
| | Needs Assessment | 2 | 2018 | 404 | 0.220 |
Why?
| | Young Adult | 19 | 2023 | 14126 | 0.220 |
Why?
| | Body Composition | 2 | 2020 | 706 | 0.220 |
Why?
| | Bronchoscopy | 1 | 2026 | 227 | 0.210 |
Why?
| | Proportional Hazards Models | 7 | 2018 | 1325 | 0.210 |
Why?
| | Immune System Diseases | 1 | 2004 | 39 | 0.210 |
Why?
| | Virus Latency | 1 | 2004 | 90 | 0.210 |
Why?
| | Salvage Therapy | 1 | 2005 | 162 | 0.210 |
Why?
| | Xenobiotics | 1 | 2024 | 32 | 0.210 |
Why?
| | Dideoxynucleosides | 2 | 2014 | 24 | 0.210 |
Why?
| | Lymph Nodes | 3 | 2011 | 502 | 0.200 |
Why?
| | Curriculum | 4 | 2018 | 1060 | 0.200 |
Why?
| | Bleomycin | 2 | 2026 | 253 | 0.190 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 319 | 0.190 |
Why?
| | Program Evaluation | 2 | 2018 | 949 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 42 | 0.190 |
Why?
| | Interleukin-10 | 2 | 2023 | 310 | 0.190 |
Why?
| | Urban Population | 3 | 2026 | 491 | 0.190 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 43 | 0.180 |
Why?
| | Nevirapine | 2 | 2013 | 18 | 0.180 |
Why?
| | Lung | 8 | 2022 | 4109 | 0.180 |
Why?
| | Africa South of the Sahara | 5 | 2026 | 53 | 0.180 |
Why?
| | Neurocognitive Disorders | 2 | 2019 | 33 | 0.180 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 60 | 0.180 |
Why?
| | Myocarditis | 1 | 2023 | 102 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2021 | 676 | 0.180 |
Why?
| | Research Design | 2 | 2025 | 1137 | 0.180 |
Why?
| | Lymphocytes | 2 | 2023 | 382 | 0.180 |
Why?
| | Speech | 1 | 2022 | 77 | 0.170 |
Why?
| | Personnel Turnover | 1 | 2022 | 42 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 36 | 0.170 |
Why?
| | United States | 9 | 2023 | 15988 | 0.170 |
Why?
| | Surveys and Questionnaires | 5 | 2022 | 6053 | 0.170 |
Why?
| | Polymerase Chain Reaction | 6 | 2021 | 1054 | 0.170 |
Why?
| | Emtricitabine | 4 | 2017 | 205 | 0.170 |
Why?
| | Adolescent | 16 | 2023 | 22453 | 0.170 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2022 | 99 | 0.170 |
Why?
| | Gastrointestinal Tract | 2 | 2014 | 208 | 0.170 |
Why?
| | B-Cell Maturation Antigen | 1 | 2021 | 15 | 0.170 |
Why?
| | Selenium | 3 | 2018 | 49 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1540 | 0.170 |
Why?
| | Cognition | 4 | 2017 | 1269 | 0.160 |
Why?
| | Thinking | 1 | 2021 | 66 | 0.160 |
Why?
| | Odds Ratio | 2 | 2014 | 1077 | 0.160 |
Why?
| | Filgrastim | 4 | 2004 | 13 | 0.160 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 6 | 0.160 |
Why?
| | Intention | 1 | 2022 | 183 | 0.160 |
Why?
| | Leukapheresis | 1 | 2000 | 27 | 0.160 |
Why?
| | Pilot Projects | 5 | 2014 | 1890 | 0.150 |
Why?
| | Pyridazines | 2 | 2012 | 57 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 2 | 2000 | 420 | 0.150 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 496 | 0.150 |
Why?
| | Workplace | 1 | 2022 | 274 | 0.150 |
Why?
| | Vincristine | 1 | 2020 | 140 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2022 | 240 | 0.150 |
Why?
| | Leadership | 3 | 2018 | 409 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Weight Loss | 3 | 2020 | 837 | 0.150 |
Why?
| | Bacteria | 3 | 2018 | 889 | 0.150 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 133 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2004 | 877 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 16 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 685 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 389 | 0.140 |
Why?
| | Atherosclerosis | 1 | 2023 | 409 | 0.140 |
Why?
| | DNA Methylation | 1 | 2024 | 683 | 0.140 |
Why?
| | Exercise | 2 | 2021 | 2201 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1054 | 0.140 |
Why?
| | Basal Ganglia | 3 | 2014 | 57 | 0.140 |
Why?
| | Cerebral Cortex | 2 | 2013 | 465 | 0.140 |
Why?
| | Paclitaxel | 3 | 2026 | 256 | 0.140 |
Why?
| | Brain | 4 | 2019 | 2941 | 0.140 |
Why?
| | Violence | 1 | 2022 | 281 | 0.140 |
Why?
| | Diet | 1 | 2026 | 1275 | 0.140 |
Why?
| | Organophosphonates | 3 | 2013 | 97 | 0.140 |
Why?
| | Genes, pol | 3 | 2007 | 7 | 0.140 |
Why?
| | Mouth | 2 | 2015 | 88 | 0.140 |
Why?
| | Suicide | 2 | 2017 | 720 | 0.140 |
Why?
| | Mutation | 5 | 2016 | 4099 | 0.140 |
Why?
| | AIDS Vaccines | 1 | 2018 | 52 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1195 | 0.130 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 69 | 0.130 |
Why?
| | Nucleic Acid Conformation | 2 | 1997 | 726 | 0.130 |
Why?
| | Capacity Building | 1 | 2018 | 62 | 0.130 |
Why?
| | Drug Combinations | 2 | 2017 | 392 | 0.130 |
Why?
| | Vitamin A Deficiency | 1 | 2017 | 26 | 0.130 |
Why?
| | Multiple Myeloma | 1 | 2021 | 304 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 337 | 0.130 |
Why?
| | Didanosine | 2 | 2014 | 13 | 0.130 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 466 | 0.130 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 27 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2018 | 509 | 0.130 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 114 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5417 | 0.130 |
Why?
| | Financing, Organized | 1 | 2017 | 36 | 0.120 |
Why?
| | Dysbiosis | 2 | 2021 | 187 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 475 | 0.120 |
Why?
| | Hospitals | 1 | 2022 | 732 | 0.120 |
Why?
| | Brain Injuries, Traumatic | 1 | 2023 | 441 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 222 | 0.120 |
Why?
| | Recombinant Proteins | 4 | 2004 | 1371 | 0.120 |
Why?
| | Haiti | 2 | 2016 | 14 | 0.120 |
Why?
| | Genes, env | 2 | 2007 | 5 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 741 | 0.120 |
Why?
| | Adenine | 3 | 2013 | 339 | 0.120 |
Why?
| | Lymphocyte Activation | 3 | 2018 | 1126 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2023 | 893 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2014 | 631 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2013 | 966 | 0.120 |
Why?
| | Herpes Simplex | 1 | 2017 | 98 | 0.120 |
Why?
| | Tetrahymena thermophila | 1 | 1996 | 68 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2019 | 284 | 0.120 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 26 | 0.120 |
Why?
| | Ghana | 1 | 2015 | 43 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 852 | 0.120 |
Why?
| | TRPP Cation Channels | 1 | 2016 | 74 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2013 | 2931 | 0.120 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 464 | 0.120 |
Why?
| | Muscle Strength | 1 | 2018 | 330 | 0.110 |
Why?
| | Ambulances | 1 | 2015 | 53 | 0.110 |
Why?
| | DNA, Protozoan | 1 | 2015 | 32 | 0.110 |
Why?
| | RNA, Protozoan | 1 | 1995 | 60 | 0.110 |
Why?
| | Hepatitis B, Chronic | 1 | 2015 | 22 | 0.110 |
Why?
| | Liver | 1 | 2024 | 1888 | 0.110 |
Why?
| | Plasmodium falciparum | 1 | 2015 | 39 | 0.110 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 476 | 0.110 |
Why?
| | Rhodobacter sphaeroides | 3 | 1983 | 7 | 0.110 |
Why?
| | Chemokine CXCL10 | 1 | 2015 | 39 | 0.110 |
Why?
| | Military Personnel | 1 | 2023 | 747 | 0.110 |
Why?
| | Cerebrospinal Fluid | 1 | 2015 | 88 | 0.110 |
Why?
| | Clinical Competence | 2 | 2021 | 1244 | 0.110 |
Why?
| | Retroviridae Infections | 1 | 1995 | 47 | 0.110 |
Why?
| | Research | 1 | 2018 | 431 | 0.110 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 142 | 0.110 |
Why?
| | Malaria | 1 | 2015 | 73 | 0.110 |
Why?
| | Anthracyclines | 1 | 2014 | 47 | 0.110 |
Why?
| | Cytomegalovirus | 1 | 2015 | 168 | 0.100 |
Why?
| | Health Occupations | 1 | 2014 | 36 | 0.100 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.100 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.100 |
Why?
| | Caribbean Region | 2 | 2011 | 30 | 0.100 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 246 | 0.100 |
Why?
| | Time Factors | 3 | 2015 | 7183 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2015 | 539 | 0.100 |
Why?
| | Exercise Therapy | 1 | 2018 | 473 | 0.100 |
Why?
| | Stavudine | 1 | 2013 | 6 | 0.100 |
Why?
| | Syphilis | 1 | 2014 | 33 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 439 | 0.100 |
Why?
| | Phylogeny | 3 | 2008 | 1019 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2015 | 172 | 0.100 |
Why?
| | Biota | 1 | 2013 | 35 | 0.100 |
Why?
| | Tropheryma | 1 | 2013 | 6 | 0.100 |
Why?
| | HIV Antigens | 3 | 2015 | 17 | 0.100 |
Why?
| | Whipple Disease | 1 | 2013 | 7 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2013 | 29 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 16 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 114 | 0.100 |
Why?
| | Genitalia, Male | 1 | 2013 | 11 | 0.100 |
Why?
| | Body Fat Distribution | 1 | 2013 | 45 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2012 | 193 | 0.100 |
Why?
| | Retinal Detachment | 1 | 2014 | 73 | 0.100 |
Why?
| | Problem-Based Learning | 1 | 2014 | 98 | 0.100 |
Why?
| | Peptide Fragments | 3 | 2007 | 699 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 557 | 0.100 |
Why?
| | Genitalia, Female | 1 | 2013 | 42 | 0.100 |
Why?
| | Hospitals, University | 1 | 2013 | 176 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2013 | 824 | 0.090 |
Why?
| | Fever | 2 | 2021 | 312 | 0.090 |
Why?
| | Genetic Therapy | 1 | 1995 | 313 | 0.090 |
Why?
| | Pregnancy | 5 | 2018 | 7191 | 0.090 |
Why?
| | Frail Elderly | 1 | 2013 | 134 | 0.090 |
Why?
| | Suicidal Ideation | 2 | 2017 | 577 | 0.090 |
Why?
| | Prostatitis | 1 | 1992 | 17 | 0.090 |
Why?
| | Hepatitis B | 1 | 2013 | 66 | 0.090 |
Why?
| | Aspergillosis | 1 | 1992 | 23 | 0.090 |
Why?
| | Muscles | 1 | 2013 | 333 | 0.090 |
Why?
| | Metagenome | 1 | 2013 | 149 | 0.090 |
Why?
| | RNA Stability | 1 | 2013 | 119 | 0.090 |
Why?
| | Heart Failure | 1 | 2025 | 2323 | 0.090 |
Why?
| | Urinary Catheterization | 1 | 1992 | 33 | 0.090 |
Why?
| | Weight Gain | 1 | 2016 | 559 | 0.090 |
Why?
| | Respiratory System | 1 | 2013 | 149 | 0.090 |
Why?
| | Movement | 1 | 2014 | 294 | 0.090 |
Why?
| | Withholding Treatment | 1 | 2012 | 81 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 250 | 0.090 |
Why?
| | Universities | 1 | 2014 | 452 | 0.090 |
Why?
| | Unsafe Sex | 1 | 2012 | 61 | 0.090 |
Why?
| | Body Weight | 1 | 2016 | 978 | 0.090 |
Why?
| | HIV Core Protein p24 | 3 | 2006 | 32 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.090 |
Why?
| | Catheters, Indwelling | 1 | 1992 | 96 | 0.090 |
Why?
| | Echocardiography | 2 | 2026 | 652 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1217 | 0.090 |
Why?
| | Exanthema | 1 | 2012 | 84 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 863 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 923 | 0.080 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 207 | 0.080 |
Why?
| | Neuropsychological Tests | 4 | 2019 | 1137 | 0.080 |
Why?
| | CD4 Antigens | 1 | 2011 | 139 | 0.080 |
Why?
| | Smoking | 2 | 2020 | 1472 | 0.080 |
Why?
| | Polyneuropathies | 1 | 2011 | 57 | 0.080 |
Why?
| | Corpus Callosum | 1 | 2011 | 72 | 0.080 |
Why?
| | Americas | 1 | 2010 | 26 | 0.080 |
Why?
| | Mycobacterium tuberculosis | 2 | 2012 | 337 | 0.080 |
Why?
| | Piperazines | 1 | 1993 | 381 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 415 | 0.080 |
Why?
| | Veterans | 1 | 2023 | 1603 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 220 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2014 | 427 | 0.080 |
Why?
| | Bone and Bones | 1 | 2013 | 315 | 0.080 |
Why?
| | Body Mass Index | 3 | 2014 | 2438 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 559 | 0.080 |
Why?
| | Patient Compliance | 1 | 2014 | 589 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 370 | 0.080 |
Why?
| | Antigens, Viral | 2 | 2021 | 182 | 0.080 |
Why?
| | HIV Reverse Transcriptase | 2 | 2004 | 31 | 0.080 |
Why?
| | Interleukin-6 | 3 | 2022 | 780 | 0.080 |
Why?
| | Endothelial Cells | 2 | 2024 | 870 | 0.080 |
Why?
| | Specimen Handling | 1 | 2011 | 186 | 0.080 |
Why?
| | HIV Fusion Inhibitors | 2 | 2007 | 3 | 0.080 |
Why?
| | HIV Envelope Protein gp41 | 2 | 2007 | 11 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2013 | 131 | 0.070 |
Why?
| | Bone Density | 1 | 2013 | 482 | 0.070 |
Why?
| | Health Personnel | 1 | 2016 | 748 | 0.070 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 158 | 0.070 |
Why?
| | Smokers | 2 | 2020 | 137 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 354 | 0.070 |
Why?
| | Neuroimaging | 1 | 2011 | 292 | 0.070 |
Why?
| | RNA | 1 | 1995 | 940 | 0.070 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2006 | 175 | 0.070 |
Why?
| | Uganda | 1 | 2008 | 93 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 787 | 0.070 |
Why?
| | South Africa | 3 | 2016 | 261 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 573 | 0.070 |
Why?
| | Cytokines | 3 | 2021 | 2065 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1327 | 0.070 |
Why?
| | Base Composition | 2 | 1997 | 82 | 0.060 |
Why?
| | Sweating | 1 | 2007 | 41 | 0.060 |
Why?
| | Blood Vessels | 1 | 2008 | 171 | 0.060 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2157 | 0.060 |
Why?
| | Organizational Culture | 2 | 2018 | 162 | 0.060 |
Why?
| | Vitamin A | 2 | 2018 | 59 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2018 | 215 | 0.060 |
Why?
| | Colorado | 3 | 2012 | 4564 | 0.060 |
Why?
| | Purine Nucleosides | 1 | 2006 | 4 | 0.060 |
Why?
| | Dioxolanes | 1 | 2006 | 6 | 0.060 |
Why?
| | Gender Identity | 1 | 2007 | 121 | 0.060 |
Why?
| | Peru | 2 | 2016 | 62 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 38 | 0.060 |
Why?
| | Program Development | 2 | 2018 | 370 | 0.060 |
Why?
| | Substrate Specificity | 2 | 1997 | 392 | 0.060 |
Why?
| | DNA, Bacterial | 3 | 2019 | 342 | 0.060 |
Why?
| | Biopsy | 2 | 2020 | 1077 | 0.060 |
Why?
| | Phospholipids | 3 | 1983 | 213 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2023 | 17101 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 2119 | 0.060 |
Why?
| | Selection Bias | 1 | 2005 | 38 | 0.060 |
Why?
| | Disease Reservoirs | 1 | 2004 | 25 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2024 | 28 | 0.050 |
Why?
| | Dizziness | 2 | 2018 | 101 | 0.050 |
Why?
| | HIV Protease | 1 | 2004 | 4 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2024 | 15 | 0.050 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2004 | 55 | 0.050 |
Why?
| | Linear Models | 3 | 2011 | 854 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1660 | 0.050 |
Why?
| | Double-Blind Method | 3 | 2018 | 2029 | 0.050 |
Why?
| | WT1 Proteins | 1 | 2024 | 12 | 0.050 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 19 | 0.050 |
Why?
| | Base Sequence | 3 | 1996 | 2191 | 0.050 |
Why?
| | Syndrome | 1 | 2004 | 380 | 0.050 |
Why?
| | Castleman Disease | 1 | 2003 | 16 | 0.050 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2023 | 56 | 0.050 |
Why?
| | Animals | 7 | 2024 | 38109 | 0.050 |
Why?
| | Aspartic Acid | 2 | 2014 | 88 | 0.050 |
Why?
| | Glucuronosyltransferase | 1 | 2023 | 18 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2003 | 33 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1915 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2023 | 163 | 0.050 |
Why?
| | Hospitalization | 2 | 2025 | 2434 | 0.050 |
Why?
| | Reference Values | 2 | 2016 | 798 | 0.050 |
Why?
| | United Kingdom | 2 | 2014 | 338 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2147 | 0.050 |
Why?
| | Speech Intelligibility | 1 | 2022 | 4 | 0.050 |
Why?
| | Speech Production Measurement | 1 | 2022 | 12 | 0.050 |
Why?
| | Binding Sites | 2 | 1996 | 1331 | 0.050 |
Why?
| | Choline | 2 | 2014 | 136 | 0.050 |
Why?
| | Lip | 1 | 2022 | 22 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2006 | 784 | 0.050 |
Why?
| | Jaw | 1 | 2022 | 27 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 402 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 983 | 0.050 |
Why?
| | Tongue | 1 | 2022 | 76 | 0.040 |
Why?
| | Lopinavir | 2 | 2013 | 30 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2023 | 239 | 0.040 |
Why?
| | Risk Assessment | 2 | 2025 | 3676 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 80 | 0.040 |
Why?
| | Ritonavir | 2 | 2013 | 75 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3869 | 0.040 |
Why?
| | Deoxycytidine | 2 | 2014 | 221 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 674 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 91 | 0.040 |
Why?
| | Frontal Lobe | 2 | 2014 | 160 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.040 |
Why?
| | Vidarabine | 1 | 2021 | 32 | 0.040 |
Why?
| | Rural Population | 1 | 2026 | 650 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2171 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 81 | 0.040 |
Why?
| | Hemoglobins | 1 | 2023 | 384 | 0.040 |
Why?
| | Regression Analysis | 2 | 2014 | 1003 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2001 | 177 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2008 | 3415 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 557 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 312 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 341 | 0.040 |
Why?
| | Prognosis | 2 | 2026 | 4293 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 266 | 0.040 |
Why?
| | Cell Line | 3 | 2001 | 2882 | 0.040 |
Why?
| | Cells, Cultured | 4 | 2008 | 4155 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1990 | 0.040 |
Why?
| | Cough | 1 | 2021 | 124 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 851 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 2000 | 88 | 0.040 |
Why?
| | Fatty Acids | 1 | 1983 | 452 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 156 | 0.040 |
Why?
| | Virion | 1 | 2000 | 111 | 0.040 |
Why?
| | Brazil | 2 | 2016 | 180 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 322 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2001 | 366 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 735 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2022 | 842 | 0.040 |
Why?
| | Nitriles | 2 | 2012 | 205 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2019 | 73 | 0.040 |
Why?
| | Teacher Training | 1 | 2018 | 10 | 0.030 |
Why?
| | Atrophy | 1 | 2019 | 201 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 85 | 0.030 |
Why?
| | Genes, vpr | 1 | 1997 | 1 | 0.030 |
Why?
| | Motor Skills | 1 | 2019 | 104 | 0.030 |
Why?
| | Genes, vif | 1 | 1997 | 3 | 0.030 |
Why?
| | Trace Elements | 1 | 2018 | 52 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 122 | 0.030 |
Why?
| | Back Pain | 1 | 2018 | 52 | 0.030 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2017 | 9 | 0.030 |
Why?
| | DNA Primers | 2 | 1996 | 512 | 0.030 |
Why?
| | Stillbirth | 1 | 2018 | 77 | 0.030 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2017 | 8 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 191 | 0.030 |
Why?
| | Adenoviridae | 1 | 2018 | 199 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 198 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2018 | 120 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1048 | 0.030 |
Why?
| | Colon | 1 | 2020 | 305 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 192 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1407 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2018 | 146 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 194 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2018 | 337 | 0.030 |
Why?
| | Seroconversion | 1 | 2017 | 49 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 555 | 0.030 |
Why?
| | Oligoribonucleotides | 1 | 1996 | 52 | 0.030 |
Why?
| | Benzoxazoles | 1 | 1996 | 20 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2018 | 272 | 0.030 |
Why?
| | Ruthenium Red | 1 | 2016 | 7 | 0.030 |
Why?
| | Amiloride | 1 | 2016 | 25 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 18 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 479 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 57 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 847 | 0.030 |
Why?
| | Pyrimidines | 2 | 2012 | 533 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 366 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 848 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 719 | 0.030 |
Why?
| | Age Factors | 2 | 2016 | 3335 | 0.030 |
Why?
| | India | 1 | 2016 | 218 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 354 | 0.030 |
Why?
| | Catalysis | 1 | 1996 | 322 | 0.030 |
Why?
| | Parasitemia | 1 | 2015 | 15 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 73 | 0.030 |
Why?
| | pol Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 1 | 0.030 |
Why?
| | Hepatitis B virus | 1 | 2015 | 33 | 0.030 |
Why?
| | Point Mutation | 1 | 2016 | 243 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 336 | 0.030 |
Why?
| | Tetrahymena | 1 | 1995 | 158 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 193 | 0.030 |
Why?
| | Carotenoids | 1 | 2015 | 48 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2015 | 69 | 0.030 |
Why?
| | RNA Splicing | 1 | 1996 | 285 | 0.030 |
Why?
| | Pyridones | 1 | 1996 | 199 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1813 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1999 | 749 | 0.030 |
Why?
| | Vitamin E | 1 | 2015 | 121 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 105 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1423 | 0.030 |
Why?
| | Schools, Health Occupations | 1 | 2014 | 8 | 0.030 |
Why?
| | Genetic Markers | 1 | 2015 | 331 | 0.030 |
Why?
| | Retreatment | 1 | 2014 | 77 | 0.030 |
Why?
| | Premature Birth | 1 | 2018 | 380 | 0.030 |
Why?
| | Developed Countries | 1 | 2014 | 38 | 0.030 |
Why?
| | Mice | 2 | 2024 | 18365 | 0.030 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 38 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 357 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2032 | 0.030 |
Why?
| | Creatine | 1 | 2014 | 63 | 0.030 |
Why?
| | Psychology | 1 | 2014 | 88 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2014 | 98 | 0.030 |
Why?
| | Group Processes | 1 | 2014 | 64 | 0.020 |
Why?
| | Protons | 1 | 2014 | 95 | 0.020 |
Why?
| | Educational Status | 1 | 2016 | 467 | 0.020 |
Why?
| | Raltegravir Potassium | 1 | 2013 | 18 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 94 | 0.020 |
Why?
| | Bronchoalveolar Lavage | 1 | 2013 | 89 | 0.020 |
Why?
| | Inositol | 1 | 2013 | 25 | 0.020 |
Why?
| | Gray Matter | 1 | 2014 | 92 | 0.020 |
Why?
| | Skin | 1 | 2018 | 758 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2013 | 17 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 612 | 0.020 |
Why?
| | Phenotype | 2 | 2014 | 3164 | 0.020 |
Why?
| | Kinetics | 1 | 1996 | 1629 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5997 | 0.020 |
Why?
| | Oligopeptides | 1 | 2014 | 269 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 264 | 0.020 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 235 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 539 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 401 | 0.020 |
Why?
| | Risk | 1 | 2015 | 911 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 428 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2609 | 0.020 |
Why?
| | White Matter | 1 | 2014 | 154 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2012 | 131 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 1993 | 371 | 0.020 |
Why?
| | Cause of Death | 1 | 2014 | 472 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2003 | 1980 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Blood Coagulation | 1 | 2013 | 268 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 598 | 0.020 |
Why?
| | Zebrafish | 1 | 2016 | 528 | 0.020 |
Why?
| | Psychological Tests | 1 | 2012 | 132 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 635 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2013 | 251 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 465 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1173 | 0.020 |
Why?
| | Headache | 1 | 2012 | 150 | 0.020 |
Why?
| | Mood Disorders | 1 | 2012 | 140 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2014 | 582 | 0.020 |
Why?
| | Biological Specimen Banks | 1 | 2011 | 103 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 489 | 0.020 |
Why?
| | Mozambique | 1 | 2010 | 7 | 0.020 |
Why?
| | Suicide, Attempted | 1 | 2014 | 422 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 605 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1958 | 0.020 |
Why?
| | Calcium | 1 | 2016 | 1184 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 652 | 0.020 |
Why?
| | North America | 1 | 2011 | 310 | 0.020 |
Why?
| | Pyrimidinones | 1 | 2010 | 126 | 0.020 |
Why?
| | Gene Expression | 1 | 1995 | 1490 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 427 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1982 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1095 | 0.020 |
Why?
| | Neuroglia | 1 | 2010 | 172 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2011 | 216 | 0.020 |
Why?
| | Thalamus | 1 | 2010 | 126 | 0.020 |
Why?
| | Students, Medical | 1 | 2014 | 375 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 405 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 463 | 0.020 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2118 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 121 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 792 | 0.020 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 111 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 302 | 0.020 |
Why?
| | Caspase 3 | 1 | 2008 | 238 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2006 | 45 | 0.020 |
Why?
| | Fluorides | 1 | 2006 | 49 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 965 | 0.020 |
Why?
| | Polyurethanes | 1 | 2006 | 38 | 0.020 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 10 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 758 | 0.010 |
Why?
| | Methacrylates | 1 | 2006 | 119 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 368 | 0.010 |
Why?
| | Computer Simulation | 1 | 2010 | 1026 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 881 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 737 | 0.010 |
Why?
| | Guanosine Tetraphosphate | 1 | 1983 | 5 | 0.010 |
Why?
| | Cerulenin | 1 | 1983 | 1 | 0.010 |
Why?
| | Linolenic Acids | 1 | 1983 | 1 | 0.010 |
Why?
| | Linoleic Acids | 1 | 1983 | 6 | 0.010 |
Why?
| | Oleic Acids | 1 | 1983 | 12 | 0.010 |
Why?
| | Light | 2 | 1983 | 411 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2925 | 0.010 |
Why?
| | Linoleic Acid | 1 | 1983 | 44 | 0.010 |
Why?
| | Oleic Acid | 1 | 1983 | 42 | 0.010 |
Why?
| | Nucleotides | 1 | 1983 | 128 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 1983 | 98 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1983 | 83 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1822 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2001 | 37 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 1981 | 68 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8279 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 560 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2430 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1718 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 1998 | 29 | 0.010 |
Why?
| | Infant | 1 | 2012 | 10039 | 0.010 |
Why?
| | Substance Abuse, Intravenous | 1 | 1998 | 128 | 0.010 |
Why?
| | Antipyrine | 1 | 1996 | 12 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 70 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 401 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1996 | 601 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 1981 | 76 | 0.000 |
Why?
| | Cell Division | 1 | 1981 | 766 | 0.000 |
Why?
|
|
Campbell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|